154 related articles for article (PubMed ID: 1318313)
41. Positive and negative regulation of a tumor necrosis factor response in melanoma cells.
Johnson SE; Baglioni C
J Biol Chem; 1990 Apr; 265(12):6642-9. PubMed ID: 2324095
[TBL] [Abstract][Full Text] [Related]
42. Control of plasminogen-activator inhibitor type 2 gene expression in the differentiation of monocytic cells.
Antalis TM; Dickinson JL
Eur J Biochem; 1992 Apr; 205(1):203-9. PubMed ID: 1555580
[TBL] [Abstract][Full Text] [Related]
43. Plasminogen activator regulation in osteoblasts: parathyroid hormone inhibition of type-1 plasminogen activator inhibitor and its mRNA.
Fukumoto S; Allan EH; Yee JA; Gelehrter TD; Martin TJ
J Cell Physiol; 1992 Aug; 152(2):346-55. PubMed ID: 1322417
[TBL] [Abstract][Full Text] [Related]
44. The novel anti-tumour agent oxamflatin differentially regulates urokinase and plasminogen activator inhibitor type 2 expression and inhibits urokinase-mediated proteolytic activity.
Dear AE; Medcalf RL
Biochim Biophys Acta; 2000 Jun; 1492(1):15-22. PubMed ID: 11004477
[TBL] [Abstract][Full Text] [Related]
45. Transcriptional regulation of the tissue-type plasminogen-activator gene in human endothelial cells: identification of nuclear factors that recognise functional elements in the tissue-type plasminogen-activator gene promoter.
Costa M; Shen Y; Maurer F; Medcalf RL
Eur J Biochem; 1998 Nov; 258(1):123-31. PubMed ID: 9851700
[TBL] [Abstract][Full Text] [Related]
46. Inhibition of protein phosphatases by okadaic acid induces AP1 in human T cells.
Thévenin C; Kim SJ; Kehrl JH
J Biol Chem; 1991 May; 266(15):9363-6. PubMed ID: 1851743
[TBL] [Abstract][Full Text] [Related]
47. Differential regulation of plasminogen activation in normal keratinocytes and SCC-4 cells by fibroblasts.
Boxman IL; Quax PH; Löwik CW; Papapoulos SE; Verheijen J; Ponec M
J Invest Dermatol; 1995 Mar; 104(3):374-8. PubMed ID: 7861005
[TBL] [Abstract][Full Text] [Related]
48. Thyroid hormones stabilize acetylcholinesterase mRNA in neuro-2A cells that overexpress the beta 1 thyroid receptor.
Puymirat J; Etongue-Mayer P; Dussault JH
J Biol Chem; 1995 Dec; 270(51):30651-6. PubMed ID: 8530502
[TBL] [Abstract][Full Text] [Related]
49. Phorbol ester induces the biosynthesis of glycosylated and nonglycosylated plasminogen activator inhibitor 2 in high excess over urokinase-type plasminogen activator in human U-937 lymphoma cells.
Genton C; Kruithof EK; Schleuning WD
J Cell Biol; 1987 Mar; 104(3):705-12. PubMed ID: 3102504
[TBL] [Abstract][Full Text] [Related]
50. The THP-1 cell line is a urokinase-secreting mononuclear phagocyte with a novel defect in the production of plasminogen activator inhibitor-2.
Gross TJ; Sitrin RG
J Immunol; 1990 Mar; 144(5):1873-9. PubMed ID: 2307845
[TBL] [Abstract][Full Text] [Related]
51. Antithrombotic regulation in human endothelial cells by fibrinolytic factors.
Fukao H; Matsuo O
Semin Thromb Hemost; 2000; 26(1):33-8. PubMed ID: 10805279
[TBL] [Abstract][Full Text] [Related]
52. Contrasting effects of two tumour promoters, phorbol myristate acetate and okadaic acid, on T-cell responses and activation of p42 MAP-kinase/ERK-2.
Amaral MC; Casillas AM; Nel AE
Immunology; 1993 May; 79(1):24-31. PubMed ID: 8389730
[TBL] [Abstract][Full Text] [Related]
53. Induction of urokinase-type plasminogen activator receptor by IL-1 beta.
Hasegawa T; Sorensen L; Dohi M; Rao NV; Hoidal JR; Marshall BC
Am J Respir Cell Mol Biol; 1997 Jun; 16(6):683-92. PubMed ID: 9191470
[TBL] [Abstract][Full Text] [Related]
54. Regulation of plasminogen activators in human thyroid follicular cells and their relationship to differentiated function.
Susarla R; Watkinson JC; Eggo MC
J Cell Physiol; 2007 Sep; 212(3):643-54. PubMed ID: 17458906
[TBL] [Abstract][Full Text] [Related]
55. Plasminogen activator inhibitor type 2 gene induction by tumor necrosis factor and phorbol ester involves transcriptional and post-transcriptional events. Identification of a functional nonameric AU-rich motif in the 3'-untranslated region.
Maurer F; Medcalf RL
J Biol Chem; 1996 Oct; 271(42):26074-80. PubMed ID: 8824249
[TBL] [Abstract][Full Text] [Related]
56. Identification of determinants involved in binding of tissue-type plasminogen activator-plasminogen activator inhibitor type 1 complexes to HepG2 cells.
Morton PA; Owensby DA; Wun TC; Billadello JJ; Schwartz AL
J Biol Chem; 1990 Aug; 265(24):14093-9. PubMed ID: 2167306
[TBL] [Abstract][Full Text] [Related]
57. Treatment of mouse L-cells with phorbol myristate acetate induces the secretion of a plasminogen activator inhibitor which binds to human and mouse urokinase and human tissue plasminogen activator.
Rehemtulla A; Gates J; Hart DA
Comp Biochem Physiol B; 1987; 88(1):277-83. PubMed ID: 3119281
[TBL] [Abstract][Full Text] [Related]
58. Modulation of procoagulant and fibrinolytic system components of mesothelial cells by inflammatory mediators.
Sitter T; Toet K; Fricke H; Schiffl H; Held E; Kooistra T
Am J Physiol; 1996 Nov; 271(5 Pt 2):R1256-63. PubMed ID: 8945961
[TBL] [Abstract][Full Text] [Related]
59. Effect of oxidative stress on the expression of t-PA, u-PA, u-PAR, and PAI-1 in endothelial cells.
Oszajca K; Bieniasz M; Brown G; Swiatkowska M; Bartkowiak J; Szemraj J
Biochem Cell Biol; 2008 Dec; 86(6):477-86. PubMed ID: 19088796
[TBL] [Abstract][Full Text] [Related]
60. Post-transcriptional stabilization of urokinase plasminogen activator mRNA by 2,3,7,8-tetrachlorodibenzo-p-dioxin in a human keratinocyte cell line.
Gaido KW; Maness SC
Toxicol Appl Pharmacol; 1995 Jul; 133(1):34-42. PubMed ID: 7597708
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
